102 results match your criteria: "Institute of Pulmocare & Research IPCR[Affiliation]"
Eur Respir J
June 2023
Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University, German Center for Lung Research (DZL), Marburg, Germany.
https://bit.ly/41wJzhk
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
September 2023
Optimum Patient Care Global, Cambridge, United Kingdom; Observational and Pragmatic Research Institute, Singapore; Division of Applied Health Sciences, Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom. Electronic address:
Background: Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS) nor been compared with effectiveness of continuing with HOCS alone.
Objective: To examine the effectiveness of initiating biologics in a large, real-world cohort of adult patients with severe asthma and HOCS.
Methods: This was a propensity score-matched, prospective cohort study using data from the International Severe Asthma Registry.
Respir Res
May 2023
National Heart and Lung Institute, Imperial College London, 1B Manresa Road, London, SW3 6LR, UK.
Background: Spirometric small airways obstruction (SAO) is common in the general population. Whether spirometric SAO is associated with respiratory symptoms, cardiometabolic diseases, and quality of life (QoL) is unknown.
Methods: Using data from the Burden of Obstructive Lung Disease study (N = 21,594), we defined spirometric SAO as the mean forced expiratory flow rate between 25 and 75% of the FVC (FEF) less than the lower limit of normal (LLN) or the forced expiratory volume in 3 s to FVC ratio (FEV/FVC) less than the LLN.
Lung India
January 2023
Department of Biotechnology and Dr. B. C. Guha Centre for Genetic Engineering and Biotechnology, University of Calcutta, Kolkata, West Bengal, India.
Clinical Trial Registration: ECR/159/Inst/WB/2013/RR-20.
Background: Glycopyrronium bromide (a long-acting antimuscarinic agent: LAMA) appears pharmacokinetically suitable for testing bronchodilator responsiveness as salbutamol (short-acting β2-agonist: SABA). Exploring the feasibility, acceptability, degree of reversibility with glycopyrronium, and its comparison with that of salbutamol may be intriguing.
Lung India
January 2023
Institute of Pulmocare and Research, Kolkata, West Bengal, India.
Lung India
January 2023
Department of Airway Disease, Institute of Pulmocare and Research, Kolkata, West Bengal, India.
Background: The pandemic-specific lockdown may influence the health status of patients with chronic airflow obstruction (CAO) as COPD, COPD-PH, and chronic asthma.
Objectives: To find the impact of the lockdown on symptoms, and the degree of perceived change in physical activity and emotional health with possible reasons including the indicators of ambient air pollution.
Methods: A cohort of CAO patients was telephonically enquired regarding their perceived well-being in symptom status, physical activity, and emotional health with the perceived contribution from plausible reasons (regular medication, simple food, no pollution, and family attention) for the change; all being expressed in percentages.
Arch Bronconeumol
April 2023
Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University, German Center for Lung Research (DZL), Marburg, Germany.
Background: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/5R and to compare the effectiveness of both classes of treatment in real life.
Methods: This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti-IgE and anti-IL5/5R.
Eur Respir J
April 2023
Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University, German Center for Lung Research (DZL), Marburg, Germany.
https://bit.ly/3KCaTGe
View Article and Find Full Text PDFRespirology
April 2023
Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University, German Center for Lung Research (DZL), Marburg, Germany.
Am J Respir Crit Care Med
April 2023
Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University, German Center for Lung Research (DZL), Marburg, Germany.
Lung India
January 2022
Department of Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.
Background: We designed this randomised, open-label, parallel group, multi-centre study to investigate the efficacy and safety of glycopyrronium/formoterol, a long-acting muscarinic antagonist/long-acting β2-agonist fixed dose combination, delivered through a dry powder inhaler (DPI) in patients with chronic obstructive pulmonary disease (COPD).
Material And Methods: We randomised (1:1) patients with moderate to severe COPD (N = 356) to receive glycopyrronium 25 μg/formoterol 12 μg via DPI twice daily (GF-DPI) or glycopyrronium 50 μg monotherapy via DPI once daily (G-DPI). The primary study endpoint was the mean change from the baseline in pre-dose trough-forced expiratory volume in one second (FEV1) at 12 weeks.
Lancet Glob Health
January 2023
National Heart and Lung Institute, Imperial College London, London, UK.
Background: Small airways obstruction is a common feature of obstructive lung diseases. Research is scarce on small airways obstruction, its global prevalence, and risk factors. We aimed to estimate the prevalence of small airways obstruction, examine the associated risk factors, and compare the findings for two different spirometry parameters.
View Article and Find Full Text PDFIndian J Med Res
July 2022
Clinical Management Group, The Woolcock Institute of Medical Research, Glebe; The Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Int J Tuberc Lung Dis
December 2022
Forum of International Respiratory Societies, Lausanne, Switzerland, Pan African Thoracic Society, Congella, South Africa, SA Medical Research Council Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
Crit Rev Clin Lab Sci
March 2023
School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India.
The two common progressive lung diseases, asthma and chronic obstructive pulmonary disease (COPD), are the leading causes of morbidity and mortality worldwide. Asthma-COPD overlap, referred to as ACO, is another complex pulmonary disease that manifests itself with features of both asthma and COPD. The disease has no clear diagnostic or therapeutic guidelines, thereby making both diagnosis and treatment challenging.
View Article and Find Full Text PDFIndian J Tuberc
November 2022
Interventional Pulmonology, Yashoda Hospitals, Hyderabad, Telangana, India.
Inhalational therapy, today, happens to be the mainstay of treatment in obstructive airway diseases (OADs), such as asthma, chronic obstructive pulmonary disease (COPD), and is also in the present, used in a variety of other pulmonary and even non-pulmonary disorders. Hand-held inhalation devices may often be difficult to use, particularly for children, elderly, debilitated or distressed patients. Nebulization therapy emerges as a good option in these cases besides being useful in the home care, emergency room and critical care settings.
View Article and Find Full Text PDFInt J Infect Dis
December 2022
Regional Health Office, Bangalore, Government of India.
Ann Am Thorac Soc
March 2023
Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio.
The Sarcoidosis Diagnostic Score (SDS) has been established to quantitate the clinical features consistent with sarcoidosis in a monocentric study. We aimed to confirm the diagnostic value of SDS in a large, multicontinental study and to assess the utility of SDS in differentiating sarcoidosis from alternative diagnoses, including infectious and noninfectious granulomatous diseases. We included patients with biopsy-confirmed sarcoidosis at nine centers across the world.
View Article and Find Full Text PDFJ Asthma Allergy
October 2022
Optimum Patient Care, Cambridge, UK.
Lancet Glob Health
October 2022
Noncommunicable Disease Management Unit, WHO, Geneva, Switzerland.
Background: Asthma and chronic obstructive pulmonary disease (COPD) cause a considerable burden of morbidity and mortality in low-income and middle-income countries (LMICs). Access to safe, effective, quality-assured, and affordable essential medicines is variable. We aimed to review the existing literature relating to the availability, cost, and affordability of WHO's essential medicines for asthma and COPD in LMICs.
View Article and Find Full Text PDFEur Respir J
January 2023
National Heart and Lung Institute, Imperial College London, London, UK.
Background: Chronic obstructive pulmonary disease has been associated with exposures in the workplace. We aimed to assess the association of respiratory symptoms and lung function with occupation in the Burden of Obstructive Lung Disease study.
Methods: We analysed cross-sectional data from 28 823 adults (≥40 years) in 34 countries.
PLoS One
August 2022
Department of Pulmonary Medicine, Director, Rajasthan Hospital & Asthma Bhawan, Jaipur, Rajasthan, India.
Background: The Global Burden of Disease data suggest that respiratory diseases contribute to high morbidity in India. However, the factors responsible for high morbidity are not quite clear. Therefore, the Seasonal Waves Of Respiratory Disorders (SWORD) study was planned to estimate the point prevalence due to respiratory diseases in Indian OPD services and its association with risk factors and change in seasons.
View Article and Find Full Text PDFERJ Open Res
April 2022
Dept of Respiratory Medicine, Asthma Bhawan, Jaipur, India.
Objective: The objective of this subanalysis of data from centres across urban areas in India of the Global Asthma Network (GAN) was to study 1) the prevalence of symptoms of asthma in children and adults, 2) the change in prevalence of asthma and its trigger factors since the International Study of Asthma and Allergies in Childhood (ISAAC), and 3) current asthma treatment practice.
Methods: In this cross-sectional, multicentre, school-based and self-administered questionnaire, responses from children aged 6-7 years and 13-14 years, and their respective parents, were analysed.
Results: The GAN Phase I study included 20 084 children in the 6-7-year age group, 25 887 children in the 13-14-year age group and 81 296 parents.
Biomed Signal Process Control
August 2022
Division of Bioinformatics, Bose Institute, P-1/12 C.I.T. Scheme VII-M, Kolkata 700054, India.
Background And Objectives: The computed tomography (CT) scan facilities are crucial for diagnosis of pulmonary diseases and are overburdened during the current pandemic of novel coronavirus disease 2019 (COVID-19). (Lung Health Severity Prediction) is a web based tool that enables users to determine a score that evaluates CT scans, without radiologist intervention, and predict risk of pneumonia with features of blood examination and age of patient. It can help in early assessment of lung health severity of patients without CT-scan results and also enable monitoring of post-COVID lung health for recovered patients.
View Article and Find Full Text PDF